1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis SBIR topic focuses on developing and demonstrating a universal, species-agnostic cell culture platform. This platform should enable rapid establishment of viable, reproducible cell lines from diverse non-model species and leverage autonomous, closed-loop culture automation.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U. S. small businesses meeting SBA size standards. Specific eligibility requirements are outlined in the solicitation. Confirm the full requirements in the official notice before applying.
The current listing shows phase I: up to $250,000; Phase II: up to $1.8M (may include co-funding). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Universal Cell Culture Platform for Rapid Establishment of Species-Agnostic Cell Lines and Autonomous Culture Operations is funded by Defense Advanced Research Projects Agency (DARPA) - Biological Technologies Office. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
On June 3, 2026, four DARPA Biological Technologies Office SBIR topics close simultaneously — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Combined Phase I plus Phase II potential exceeds $6 million per company, and together they sketch a coherent strategy of distributed, autonomous, dual-species combat casualty care that depends on small businesses, not primes, to actually build.
Read articleDPA26BZ06-DV026 offers $300,000 at Phase I or $1,800,000 as a single Direct-to-Phase-II tranche with no options. The deliverable is a simulated auction market that measures whether AI agents deceive, collude, or manipulate the humans they serve — measured entirely from the outside. Here is the 90% efficiency gate, the team composition most bidders will get wrong, and why this topic sits in DARPA's biology office.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read article